Cardiologists with Asheville Cardiology Associates, an affiliate of Mission Health, are leading the way in the number of cases performed in a national clinical trial of a novel netcovered stent used in patents who have just experienced an ST Elevation Myocardial Infarction (STEMI), better known as a heart attack. More than half of the U.S. total cases performed in the trial thus far have taken place at Mission Hospital.
The first U.S. stent implantation of the trial was performed at Mission Hospital on Dec. 6, 2013. To date, eight surgeries implanting the device, the MGuardTM Prime Embolic Protection Stent (EPS) with MicroNetTM covering, have taken place at Mission. The devices are manufactured by InspireMD, which has U.S. operations headquartered in Boston, Mass.
Stents such as this one are small metal mesh devices that are placed within an artery to open a blocked section so that blood flow throughout the cardiovascular system can continue unimpeded. The FDA trial, known as MASTER II (MGuard for Acute ST Elevation Reperfusion), is the second in a series of randomized clinical studies intended to validate that the device is safe and effective, and can then be approved by the FDA for widespread use in patients in the United States.